Mechanisms of Resistance to PSMA Radioligand Therapy

Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Jun 22, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating how prostate cancer can become resistant to a specific treatment called Lutetium-based PSMA-targeted radioligand therapy (RLT). This therapy uses a radioactive substance to target and kill cancer cells that have a protein called PSMA on their surface. The study aims to better understand the reasons why some patients may not respond to this treatment as well as to gather information from patients who are just starting this therapy.

To be eligible for this trial, participants need to be at least 18 years old and starting treatment with Lutetium-based RLT. They must have a specific type of cancer lesion that can be biopsied, which means taking a small sample of tissue for testing. Patients taking blood thinners like warfarin or aspirin can still participate if they can safely stop these medications before the biopsy. Throughout the trial, participants will undergo tests and procedures to help researchers learn more about how their cancer behaves and responds to treatment. This trial is actively recruiting patients, and anyone interested should discuss it with their healthcare provider for more information.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Initiating treatment with Lutetium based PSMA-targeted RLT.
• • 2. Participants must have a PSMA-avid lesion that is accessible to biopsy. Biopsy of newly emerging radiographic metastases is desired and preferable to the biopsy of previously existing lesions whenever possible. Newly emerging lesions are defined as those that are absent on a previous scan, or those demonstrating unequivocal progression since initiation of the last treatment. Biopsies will be performed according to local institutional standards.
• • 3. Patients on warfarin, aspirin, or other anti-coagulants are eligible provided they are deemed able to tolerate discontinuation of anti-coagulation for at least five days prior to the biopsy. Conversion to low molecular weight heparin prior to biopsy is permitted per local standard operating procedures, provided there is approval by the interventional radiologist or the PI.
• • 4. Age \>=18 years.
• • 5. Ability to understand and the willingness to sign a written informed consent document.
• Exclusion Criteria:
• • 1. Patients with significant congenital or acquired bleeding disorders (eg von Wildebrand's disease, acquired bleeding factor inhibitors).
• • 2. Patients who are not able to undergo additional study related imaging procedures.